Auxagen Inc was founded to develop therapeutic agents based on newly developed technologies of TGF-β receptor antagonists and TGF-β enhancers for the treatment of wounds and tissue fibrosis which currently lacked effective therapy. Transforming growth factor-β (TGF-β) is a family of structurally homologous dimeric proteins that regulate multiple biological processes such as cell production, extracellular matrix (ECM) synthesis, angiogenesis, immune responses, apoptosis and differentiation. They have also been associated with the development of chronic wounds, tissue fibrosis, cardiovascular disease, cancer, autoimmune diseases, and other disorders. As of 2014, two products, a gel formulation for wound treatment and a aerosol formulation for treatment of lung fibrosis, are in pre-clinical tria
